Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multi-arm open-label study in extensive-stage small-cell lung cancer
2016-001202-42Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab, tremelimumab, adavosertib, ceralasertib, olaparib and 1 more in small cell lung cancer (SCLC) (4 arms), sponsored by AstraZeneca. Primary endpoint: Overall response rate. Started Aug 2016; status: completed.
02
Drugs
durvalumabtremelimumabadavosertibceralasertibolaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2016-001202-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001202-42.